140 mg silymarin PO TID
Hepatitis, Chronic Active
Silibinin constituent: 240 mg PO BID
Silymarin 70-80% extract: 420 mg/d PO
1 mL PO TID (Iberogast, Medical Futures, Inc)
Silymarin 200 mg PO TID in combination with conventional treatment
Alcoholic liver disease, appetite stimulant, gallbladder problems, hepatic cirrhosis, hepatitis (chronic), hepatotoxicity (chemical/drug-induced), jaundice, pleurisy, prostate cancer, spleen diseases
Possibly effective in diabetes and dyspepsia
Extensively studied; effective in treatment of cirrhosis, hepatitis, chemical- or alcohol-induced fatty liver
Effective in mushroom (Amanita phalloides) poisoning, if treatment begun early
IV form of silibinin approved in Europe for Amatoxin poisoning
Frequency Not Defined
Hypersensitivity to Asteraceae/Compositae plants, chrysanthemums, daisies, marigolds,
Breast cancer, endometriosis, hormone sensitive conditions, ovarian cancer, uterine cancer, uterine fibroids
Concurrent CYP3A4 substrates, CYP2C9 substrates
Silymarin has poor oral bioavailability & is sparsely water-soluble
Pregnancy & Lactation
Pregnancy Category: N/A
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Active constituents: silymarin; silibinin
Antioxidant, protects hepatocyte membranes, enhances liver parenchyma regeneration, increases glutathione levels